OIPE JC106
JUN 10 2004
PATENT & TRADEMARK OFFICE

Form PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	~~10/643,829~~ 10/682,178
Filing Date	~~August 19, 2003~~ August 9, 2003
First Named Inventor	~~LIU, His-Chou~~ Link et al
Group Art Unit	~~1632~~ 1643
Examiner Name	
Attorney Docket Number	~~P05779US01~~ P05859US01

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. [1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
ALH	1	International Search Report for co-pending PCT Application No. PCT/US03/32036	
	2	Galili U et al., "Preparation of autologous leukemia and lymphoma vaccines expressing alpha-gal epitopes", Journal of Hematotherapy and Stem Cell Research. U.S. August 2001; 10(4):501-511 August 2001	
	3	LaTemple D.C. et al., "Synthesis of α-Galactosyl Epitopes by Recombinant α1,3Galactosyltransferase for Opsonization of Human Tumor Cell Vaccines by Anti-Galactose", Cancer Research, American Association for Cancer Research, Baltimore, Md, US, 56:3069-3074; July 1996	
	4	LaTemple, Denise C. et al., "Increased Immunogenicity of tumor vaccines complexed with anti-gal: Studies in knockout mice for α1, 3galactosyltransferase", Cancer Research, American Association for Cancer Research, Baltimore, MD, US, 59(4):3417-3423; July 1999	
	5	Gorelik E., et al., "Alterations of cell surface carbohydrates and inhibition of metastatic property of murine melanomas by α1,3 galactosyltransferase gene transfection", Cancer Research, American Association for Cancer Research, Baltimore, Md, US, 55(18):4168-4173; September 1995	
	6	Galili Uri et al., "Expression of α-gal epitopes on ovarian carcinoma membranes to be used as a novel autologous tumor vaccine", Gynecologic Oncology, 90(1):100-108; July 2003	
	7	Yoshimura N. et al., "Expression of xenoantigen transformed human cancer cells to be susceptible to antibody-mediated cell killing", Cancer Letters. Ireland 164(2):155-160; March 2001	

Examiner Signature	/Anne Holleran/ (12/04/2006)	Date Considered	

* EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.